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Abstract 
Background: Antibodies have been a pillar of basic research, while their relevance in clinical diagnostics and therapy 
is constantly growing. Consequently, the production of both conventional and fragment antibodies constantly faces 
more demanding challenges for the improvement of their quantity and quality. The answer to such an increasing 
need has been the development of a wide array of formats and alternative production platforms. This review offers a 
critical comparison and evaluation of the different options to help the researchers interested in expressing recombi-
nant antibodies in their choice.
Results: Rather than the compilation of an exhaustive list of the recent publications in the field, this review intendeds 
to analyze the development of the most innovative or fast-growing strategies. These have been illustrated with some 
significant examples and, when possible, compared with the existing alternatives. Space has also been given to those 
solutions that might represent interesting opportunities or that investigate critical aspects of the production optimi-
zation but for which the available data as yet do not allow for a definitive judgment.
Conclusions: The take-home message is that there is a clear process of progressive diversification concerning the 
antibody expression platforms and an effort to yield directly application-adapted immune-reagents rather than 
generic naked antibodies that need further in vitro modification steps before becoming usable.
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Background
The worldwide therapeutic antibody market is esti-
mated as over $50b/year, diagnostic market over $10b/
year, and research market accounts for $3b/year, whereas 
the average annual growth rate for all antibody applica-
tions in the last 15  years is over 5  % and the recombi-
nant antibody sector is one of the fastest growing. These 
numbers explain clearly the interest in all the biotech-
nological innovations aimed at improving the antibody 
production process in terms of absolute yields, struc-
tural stability and functional reliability of the final prod-
uct. Specifically, the increasing attention dedicated to 
recombinant antibodies is due to the possibility of: (1) 
performing straightforward engineering by means of sim-
ple molecular biology techniques; (2) developing binders 
of variable formats and fused to different effectors and 
tags; (3) producing the final constructs inexpensively 
in microbial factories; (4) maintaining stable material 
clonality, the mandatory pre-requisite for result repro-
ducibility [1]. This trend will probably accelerate in the 
foreseeable future because of the demanding structural 
features of the emerging antibody-based reagents such 
as Immunotoxins, Antibody Drug Conjugates (ADCs), 
Bispecific Antibodies, and Bispecific T cell Engager 
(BiTE) [2, 3]. Clearly, the great structural variability of the 
designed immune-reagents has its reason in the necessity 
to obtain effective reagents that are possibly also simple 
to use. At the same time, it implies the necessity of devel-
oping customized expression and purification procedures 
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adapted to the construct specificities in order to assure 
sufficient yields. Such a complex context requires the 
capacity of comparing advantages and shortcomings of 
alternative platforms. This review aims at summarizing 
the recent trends, tries to evaluate the level of feasibility 
and reliability reached by the different methodologies, 
and will describe some recent innovative proposals.
Production of antibody fragments in prokaryotic 
systems
The conventional approach: expression in Escherichia coli 
(E. coli)
Escherichia coli still remains the most popular organism 
for recombinant protein expression and it still repre-
sents the standard for the production of antibody frag-
ments on a lab scale. There are objective advantages 
for this choice, such as its simplicity, the availability of 
a large amount of well-tested reagents (vectors, strains), 
and the enormous experience (protocols, common 
expertise) that the research community accumulated 
over the last 30 years using this specific bacterium. The 
negative side effects implicit in choosing E. coli-based 
expression systems are that this solution is often driven 
by consuetude rather than by rational considerations. 
This means that both innovative approaches that exploit 
E. coli and systems based on other organisms might 
be neglected despite their use do not always requires 
further competences or particular equipment. In the 
case of antibody fragments, the conventional approach is 
to express them as secreted constructs that accumulate 
in the E. coli periplasm because this is the sole bacterial 
compartment that provides the oxidizing conditions and 
the combination of specific chaperone and isomerase 
activities necessary for the formation of correct and sta-
bilizing disulfide bonds (Fig.  1). This approach enables 
the production of large amounts of functional antibody 
fragments and also their fusions to large proteins such 
as alkaline phosphatase and rhizavidin [4, 5]. However, 
in some cases the yields can be very low due to impaired 
secretion in the presence of too elevated expression lev-
els and because of limiting chaperone availability in the 
periplasm [6–8]. Oxidizing conditions can be repro-
duced in the cytoplasm of mutant strains (Fig.  1) in 
which the thioredoxin and glutathione reducing path-
ways are blocked (such as Origami and derivatives), 
whereas the cytoplasmic overexpression of the periplas-
mic DsbC isomerase (such as in Shuffle T7 Express) can 
rearrange disulfide bonds involving incorrect cysteine 
residues. However, the published results obtained with 
these strains are contradictory [9, 10]. Although some 
groups claim successful production of functional anti-
body fragments in their cytoplasm, when critically eval-
uated, the results often indicate very low yields, while the 
biophysical characterization necessary to assess protein 
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Fig. 1 Conventional antibody expression in E. coli. Most of the recombinant antibodies rely on the formation of disulfide bonds in order to reach 
their native structure. Periplasm is the only E. coli oxidizing compartment compatible with disulfide bond formation and consequently it has been 
considered the logic environment for antibody accumulation despite its small volume. Mutant strains (gor−/trxB−) with partially oxidizing cytoplasm 
represent an alternative (cytoplasmic accumulation) as well as expression systems that enable the antibody secretion in the medium or at the cell 
surface (antibody display)
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quality might be insufficient [11, 12]. In another case, 
the fusions between an anti-HER2 scFv and monomeric 
fluorescent proteins expressed in gor−/trxB− strain seem 
to be functional [13] but the SPR data are not compatible 
with a 1:1 binding and, consequently, cast some doubts 
that the immune-reagents form (also? active?) aggre-
gates. Some other positive reports should be considered 
carefully because of the chosen models. It is known that 
a significant portion of VHHs can accumulate as func-
tional binders even in the absence of disulfide bonds and 
that consequently they can be expressed as functional 
intrabodies in the reducing cytoplasm of bacteria (and 
even of eukaryotic cells). When such structurally robust 
VHHs are expressed in Shuffle T7 Express bacteria, the 
resulting yields are very high. However, the production 
improvement with respect to the “control” BL21(DE3) 
bacteria is negligible [14]. Unluckily, no disulfide-
dependent nanobody has been tested for comparison in 
such an experiment to evaluate the strain effectiveness 
under more demanding conditions.
Recently, antibody fragments have been produced 
very efficiently in the cytoplasm of E. coli overexpress-
ing sulfhydryl oxidase (SO) and DsbC [15, 16] (Fig.  2). 
The method seems suitable for both VHHs and scFvs 
but its major advantage is that it enables the accumula-
tion of functional immune-reagents with extremely more 
complex structural needs. It is the case of reconstituted 
IgG-like macromolecules as well as of fusions between an 
antibody fragment and proteins that have different redox 
requirements to fold correctly. The approach enabled the 
yield of tens of mg of monodispersed IgG/L using Luria–
Bertani (LB) bacterial medium without any attempt of 
culture optimization. When conventional (periplasmic) 
and SO/DsbC cytoplasmic cultures were compared using 
the same constructs, the cytoplasmic yields were always 
significantly (at least 10 times) higher. The immune-rea-
gents accumulated in the cytoplasm had also superior 
specific functional activity, indicating that folding was 
correct even in the case of complex structures such as 
IgG-like antibodies. This accomplishment appears as a 
clear improvement in comparison to the initial reports, 
which indicated the feasibility of using E. coli for IgG 
production [17, 18].
Expression rate control is a key parameter in recom-
binant production [6] and alternatives to the classical 
method based on lac promoter and its derivatives can 
contribute to higher antibody fragment yields. In the 
case of the pair formed by the Pm promoter and the ben-
zoic acid-inducible XylS transcription activator [19], the 
direct evolution of XylS resulted in mutants that enabled 
ninefold higher yields of the tested scFv-phOx construct. 





























Fig. 2 Alternative antibody expression in E. coli cytoplasm. Effective accumulation of functional recombinant antibodies can be obtained by 
expressing sulfhydryl oxidase and DsbC isomerase (a) in the cytoplasm before inducing antibody expression in the same cell compartment (b). The 
two foldases have complimentary activities: the cysteine SH groups are converted into disulfide bonds by sulfhydryl oxidase (c) and, if necessary, 
these are scrambled by DsbC to achieve the native folding (d)
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the structural and functional features of the (over)-pro-
duced immune-reagent.
The strategies used for increasing the solubility of 
recombinant proteins expressed in E. coli have preva-
lently focused on conditions known for improving folding 
efficiency. Proteins such as isomerases and chaperones 
have been overexpressed, the bacterial growth has been 
performed at low temperatures and in the presence of 
osmolytes and alcohols known for stimulating heat-shock 
response, and even specific strains have been developed 
[7–9, 20]. By contrast, the optimization of medium com-
position and fermentation conditions is often neglected 
in academia with the exception of labs performing more 
industrial-oriented R&D. However, significantly higher 
amounts of antibody fragments can be recovered when 
the physical–chemical culture conditions are improved, 
and this is possible even in the absence of sophisticated 
fermentation equipment. Cell density can be increased 
tenfold in standard Erlenmeyer flasks when bacteria are 
grown using rich medium instead of LB [14] and the 
yields can be further improved by exploiting LEX™ bio-
reactors [21] or baffled flasks in combination with opti-
mized shaking velocity [22].
A completely different approach considers that func-
tional recombinant antibodies can be obtained also by 
promoting first their accumulation in the inclusion bod-
ies and then their refolding [23]. The idea is not new, 
but its implementation was significantly improved by 
the particularly effective strategy recently proposed by 
Kumada et  al. [24]. These authors designed a high-den-
sity microplate culture system for producing in paral-
lel insoluble constructs of scFv fused with polystyrene 
binding peptides at the concentration of 1  mg/mL and 
recovered functional antibodies by solid-phase refold-
ing (Fig.  3). The efficiency of the approach is probably 
due to the fact that, after inclusion body denaturation, 
the single polypeptides adhere separately onto plastic 
plate surfaces by means of the polystyrene-affinity tag. 
This physical segregation reduces unproductive interac-
tions among folding intermediates that can still expose 
hydrophobic patches. The method was validated succes-
sively with Fab fragments and further developed using 
alternative tags suitable for alternative refolding proto-
cols [25, 26]. Its limit is that refolding efficiency is very 
sequence-dependent.
In a recent contribution [27], the yields of two con-
structs formed of the same scFv fused to the sequences 
corresponding to a toxin of either bacterial (Pseudomonas 
exotoxin A) or plant (saporin) origin were compared in 
E. coli and P. pastoris. Exotoxin A-scFv was apparently 
expressed better in bacteria, whereas saporin-scFv pro-
duction was more successful in yeast. The authors’ con-
clusions were that the toxin origin strongly influences 
the production of functional immune-reagents in evo-
lutionary related or distant organisms. This would be an 
interesting hypothesis to assess thoroughly. However, 
the experimental data are difficult to interpret since the 
immune-toxins accumulated as inclusion bodies when 
expressed in bacteria and the reported yields correspond 
to the amounts of soluble protein after refolding. Conse-
quently, the variable yields could be due to the differen-
tial refolding efficiency rather than to specificities of the 
microbial factories. Furthermore, crucial experimental 
characterizations and descriptions necessary to evaluate 
the structural features of the immune-toxins are missing 
thus rendering final judgment impossible.
A very interesting development is represented by 
the attempt of obtaining homogeneous N-glycosylated 
recombinant antibodies in E. coli with the long-term 
aim of recovering the effector functions and tissue tar-
geting specificity proper of IgG molecules [28]. The 
authors demonstrated that it is possible to achieve a 
homogenously glycosylated and degradation-resistant 
scFv by designing a glycosylation site in the linker region 
and using an E. coli strain in which the N-glycosylation 
machinery of the ε-proteobacterium Campylobacter 
In parallel IB 
producon
IB isolaon
Specific binding of 
denatured plasc-
tagged Abs Ab refolding
Fig. 3 Surface–activated refolding of recombinant antibodies. Bacteria are first forced to produce inclusion bodies formed by recombinant anti-
bodies fused to peptides affine for plastic. Once denatured, each single polypeptide adhere separately onto plastic plate surface by means of the 
peptide tag. The denatured polypeptides efficiently refold (solid-phase refolding) into functional antibodies because the unproductive interactions 
involving hydrophobic patches present at the surface of different folding intermediates are prevented
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jejuni has been transferred [28]. The post-transcriptional 
modification significantly improved the scFv stability 
and solubility, while did not affect its binding capacity 
because glycosylation has a distal location with respect to 
the antibody paratope.
Escherichia coli extract has been successfully used 
also for the cell-free production of “knobs-into-holes” 
bispecific BiTE IgG antibodies [29]. The knobs-into-
holes technology enables the pairing of complimentary 
antibody arms but the efficiency of the IgG reconstitu-
tion is low when the two complimentary molecules are 
co-expressed in cells due to the usual variable accumu-
lation rate of the two constructs. The cell-free approach 
overcomes this major drawback and results in high yields 
(several hundred mg/L) of functional antibodies that can 
be further improved by optimizing the reagent composi-
tion [30].
Alternative bacteria suitable for specific applications
Lactobacillus was the first alternative to E. coli to be 
proposed with the aim of providing biosafe bacteria 
expressing anti-viral nanobodies (lactobodies) for oral 
treatments in mammalians [31] and optimized strains 
are now available [32]. The concept considers the isola-
tion of neutralizing VHHs and their expression as either 
secreted or cell-wall-anchored antibodies. Animals fed 
with such recombinant bacteria resulted better protected 
against virus-induced gastroenteritis since the nanobod-
ies were successfully delivered in  situ by the lactobod-
ies. Lately, it has been demonstrated that VHH dimers 
targeting two independent rotavirus epitopes and com-
binations of soluble and displayed nanobodies blocking 
the same epitopes could further improve the treatment 
efficacy [33, 34] (Fig. 4). A similar philosophy led to the 
design of a system for the production of neutralizing 
scFvs in Bifidobacterium longum to use as a probiotic 
aliment [35]. The actual effectiveness of this approach 
was not demonstrated in  vivo, but recombinant bacte-
ria were able to express functional antibodies in the gut 
after intragastric administration, although the secretion 
efficiency apparently varied according to the antibody 
sequence. Although very promising as a vaccine comple-
mentary treatment, the implementation of this approach 
into approved cure for animal and human diseases [36] 
will probably suffer from the general public refusal of 
exploiting recombinant organism technology. Or, maybe, 
its simplicity will convince of the contrary.
Exotic bacteria such as the psychrophilic Pseudoalte-
romonas haloplanktis TAC125 have been proposed as 
an alternative to E. coli for VHH and scFv production 
[37, 38]. Although the choice of a microbial cell fac-
tory working at low temperature is interesting because 
it might favor the proper folding of the recombinant 
proteins, the practical advantages of this approach 
remain elusive, whereas some drawbacks should be con-
sidered, e.g. higher energy costs for bacterial culture, 
limited availability of expression vectors with applica-
tion-friendly tags. Much more convincing are the data 
published recently by Mizukami et al. [39] that illustrate 
the enormous potential of Brevibacillus choshinensis for 
expressing recombinant antibody fragments. Two VHHs 
were expressed using a secretion vector and accumu-
lated in the culture medium at concentrations of hun-
dreds of mg/L when grown in flasks and topped at 3 g/L 
when produced in fermenter. The extremely accurate 
biophysical characterization of the resulting nanobod-
ies confirms that they were functional and unquestion-
ably monodispersed. It will be very interesting to follow 
the development of this production platform based on 
the “Brevibacillus in  vivo cloning (BIC)” technology 
[40, 41] to understand if the excellent quantitative and 
qualitative features obtained with these model VHHs 
will be confirmed by using nanobodies with variable 







Fig. 4 Lactobacilli as antibody-based functional food. Lactobacilli are 
transformed with expression vectors allowing for both recombinant 
antibody display and secretion to the medium. Such bacteria (lacto-
bodies) maintain the capacity to produce recombinant antibodies 
after ingestion and promote the accumulation of virus-neutralizing 
binders in the midgut of the fed animals
Page 6 of 17de Marco  Microb Cell Fact  (2015) 14:125 
complex proteins such as scFvs cannot benefit as much 
as VHHs [40, 41] from this expression methodology. 
At the moment it is difficult to evaluate whether the 
observed limitation is intrinsic of the organism folding 
machinery or of still-to-be-optimized expression vectors 
and fermentation conditions. The available information 
is not sufficient to evaluate the possible advantages of 
expressing recombinant antibody fragments in Bacillus 
megaterium and Corynebacterium glutamicum [42, 43]. 
Also Pseudomonas putida KT2440 does not seem to be 
a superior alternative to E. coli in terms of productivity, 
but at least this strain already obtained the biosafety cer-
tificate [44] and this may constitute a critical advantage 
for the preparation of therapeutic antibody fragments.
Simplified approaches: the opportunities offered by cell 
display
Antibodies are too often considered as reagents that 
must be first expressed and purified before being used. 
Further biotechnological steps such as their functionali-
zation with appropriate molecules may be necessary to 
enable their final application, as for instance their use as 
capture binders on chip surfaces or their complexation 
to nanoparticles. However, there are examples—as in 
cases mentioned above [31, 33, 35]—showing that some 
of these tedious and expensive steps can be avoided by 
expressing recombinant antibodies as displayed rea-
gents exposed on the surface of bacteria. The therapeutic 
application of attenuated strains of VHH-displaying Sal-
monella typhimurium has been demonstrated recently 
[45]. The rationale behind the experiment is that several 
bacterial strains can contribute to tumor eradication 
in mouse models because they may induce anti-tumor 
immune-response after direct local injection. Bacteria 
show also a certain natural tropism for tumors but it is 
insufficient for effective targeted accumulation after sys-
temic treatment. To improve their tumor-delivery speci-
ficity, Salmonella has been engineered for displaying an 
anti-CD20 nanobody. Such engineered bacteria accumu-
lated selectively in CD20-positive tumor xenografts when 
applied systematically in mice and were successfully used 
as a cargo to deliver an enzyme able to convert in  situ 
pro-drugs into active compounds (Fig.  5). The efficient 
nanobody-mediated bacterial targeting resulted in a sig-
nificant tumor rejection in vivo even in immune-compro-
mised models [45]. A similar approach has been applied 
also to Lactobacillus plantarum to exploit it as a cargo to 
deliver cDNA to mammalian cells [46]. Specifically, lac-
tobacilli were transformed to display a scFv selective for 
the dendritic cell marker receptor DEC-205. The result-
ing lactobacilli were effectively internalized in  vitro and 
in vivo by dendritic cells and transferred efficiently a GFP 
plasmid to them.
In a diagnostic context, whole E. coli displaying anti-
nucleophosmin VHHs resulted very effective when 
exploited as an antigen-capture reagent to bind the sol-
uble antigen on microarray surfaces [47]. Contrary to 
the conventional approach used for biosensor surface 
immune-functionalization that relies on the availability 
of purified antibodies, bacteria were first transformed 
with a vector enabling the display of anti-target VHHs, 
the nanobody recombinant expression was induced for 
few hours, and finally the bacteria were directly spotted 
on the microarray surface. The high density of nanobod-
ies inserted outwards on the bacterial membrane (Fig. 6) 
enabled an extremely high and selective binding of the 
corresponding antigens with signal-to-noise values supe-
rior to 103 [47].
Eukaryotic expression systems for antibody 
fragments
Yeasts as microbial cell factories
The idea of displaying antibodies on whole cells has been 
long used in yeast for panning antibody libraries but 
only recently it has been proposed to exploit antibody-
displaying whole cells as ready-to-use reagents. Binders 
were first selected from a scFv pre-immune library in 
yeast display format and the recovered cells were directly 
lyophilized for storage [48]. They retained their initial 
activity and specificity and could be used for few weeks 
representing a cheap and fast alternative to purified anti-
bodies for at least some immune-capture applications 












Fig. 5 Salmonella as a tumor-targetable cargo. Salmonella can be 
transformed for displaying recombinant antibodies specific for tumor 
cell antigens and for secreting enzymes able to activate pro-drugs. 
The antibodies assure the selective accumulation of systematically 
provided bacteria in the antigen-expressing target tissue and there 
the secreted enzymes will trigger the local conversion of inactive pro-
drug into toxic compounds with anti-tumor activity
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Pichia pastoris is the workhorse yeast for conventional 
production of scFv-derived antibody fragments. The 
protocols for obtaining secreted constructs are stand-
ardized and efficient [49–51] and most of the lately pro-
posed improvements concern incremental features such 
as the length of the pre-induction glycerol feeding during 
fermentation, the codon usage, the optimization of the 
starting culture temperature, of the methanol concentra-
tion, and of pH obtained by means of Design of Experi-
ment approach [52–54].
Other yeasts are used as well for producing recombi-
nant antibodies. In Saccaromyces cerevisiae, significant 
production increases (>100 folds) were obtained by a 
combination of strain engineering and the optimization 
of leader peptides for improving the secretion of full-
length recombinant IgG molecules [55], even though 
the absolute yields remained modest (in the range of 
10  mg/L). The same yeast was exploited for producing 
pseudo-type virus-like particles that form when scFv-
Fc constructs fused to hamster polyomavirus-derived 
VP2 protein are co-expressed with the complimentary 
VP1 protein (Fig.  7). Such structures represent multi-
valent antibody nanoparticles possessing strong anti-
gen-binding and -neutralizing activities that effectively 
prevented mammalian cell lysis induced by vaginolysin 
[56]. Another approach considers the Saccaromyces dis-
play of scFvs fused to non-self-cleaving Mxe GyrA intein 
for promoting the chemical functionalization of the anti-
body fragment by exploiting the Expressed Protein Liga-
tion methodology. First, a thiol-nucleophile is used to 
release the antibody fragment from the yeast surface. As 
a consequence, the antibody acquires a thioester group at 
the carboxy-terminal that becomes available for binding 
covalently any molecule with an amino-terminal cysteine 
[57]. In such a way, the authors incorporated azido 
groups and biotinylated peptides into an anti-EGFR scFv. 
The production of antibody fragments (scFv-GFP fusion) 
in the fission yeast Schizosaccharomyces pombe seems 
possible [58] but does not exemplify an apparent advan-
tage over other yeast- and prokaryotic-based systems.
Despite the fact that P. pastoris is one of the most 






Fig. 6 Purification-independent antibody-antigen recognition. The recombinant antibody expression is first induced in bacteria transformed with a 
membrane display vector. As a consequence, in few hours outward-oriented antibodies accumulate at the bacterial surface. The antibody-display-
ing bacteria are directly spotted on a chip surface. The displayed antibodies specifically capture the corresponding antigens that are labeled and 
quantified after a washing step necessary to remove the contaminants
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scFv and scFv-fusion proteins, only few reports describe 
the production of nanobodies in this yeast species. Since 
for many research labs yeast production might be tech-
nically more demanding than the golden standard E. 
coli, the choice would become meaningful only when 
specific advantages can be obtained. This evidence was 
missing in the first paper describing the production of a 
naked single-domain antibody in P. pastoris. Yields were 
comparable (10 mg/L) with those obtained with most of 
the VHHs expressed in bacteria [59]. The approach was 
more clearly justified in the work of Ji et al. [60] who used 
Pichia to express the IgG-like construct composed by 
an anti-TNF VHH fused with a human Fc. The authors 
found that it was more functionally active than the same 
construct expressed in the periplasm of E. coli. Never-
theless, the exact reasons of the functional advantage 
remain unknown since the authors did not characterize 
the recombinant antibodies for their structural features. 
In terms of yields, these were lower (5  mg/L) in com-
parison to what was obtained by Djender et al. [16] who 
expressed comparable constructs in bacterial cytoplasm. 
S. cerevisiae offers an interesting alternative to Pichia, 
but despite some promising initial results [61], it has 
never become a popular expression systems for VHHs. 
Recently, an important contribution assessed the role of 
specific residues in the VHH sequences the optimization 
of which might contribute substantially to improve their 
final yields in S. cerevisiae [62]. Specifically, the authors 
identified that some amino acids close to and inside the 
J segment are critical for VHH folding and secretion in 
yeast because they are involved in the chaperone recruit-
ment in the ER. Their presence compensates for the rec-
ognition differences that exist between the mammalian 
and S. cerevisiae chaperone machineries and favor the 
VHH folding kinetics.
Any good reason for expressing recombinant antibodies 
in mammalian cells?
Mammalian cells represent the gold standard for produc-








Fig. 7 Multivalent antibody nanoparticles. Virus proteins can assemble into virus-like particles also when one of them is fused to antibody frag-
ments. The outcome is represented by multivalent nanostructures exposing active antibodies. The nanostructure high avidity confers elevated 
neutralizing effect
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other systems have been preferred. However, the mam-
malian origin of VHH and scFv fragments suggests that 
it could be meaningful not only to produce them in yeast 
co-expressing mammalian chaperones [62], but directly 
in evolutionarily related organisms such as mamma-
lian cells that should possess conserved secretion/fold-
ing machineries. The resulting antibodies are expected 
to gain the specific post-transcriptional modifications 
that enable the immune-activation and target recogni-
tion mechanisms in mammalians. This would represent 
a clear advantage for evaluating the in  vivo biological 
activity of antibodies conceived for therapeutic applica-
tions. From this perspective, it would be very interest-
ing to have access to comparative studies evaluating the 
binding characteristics, the biodistribution and pharma-
cokinetic, the immunogenic and curative effects, and the 
production costs of recombinant antibodies expressed 
in different organisms. However, sufficient information 
is not available so far with only few reports of antibody 
fragments produced in mammalians, such as a VHH 
against GFP expressed in CHO cells and scFv-Fc frag-
ments against Epstein Barr virus in HEK293 [63, 64]. It is 
difficult to infer from this lack of data if the scarce inter-
est finds its reasons in technical, biological or economic 
considerations.
Filamentous fungi, insect‑based systems and further 
“niche” eukaryotic organisms
Trichoderma reesei and Aspergillus spp failed to achieve 
the leading role in the production of recombinant nano-
bodies that was envisaged almost 15  years ago [61]. As 
suggested at that time, these expression systems should 
have been particularly effective for producing fusion pro-
teins composed of antibody fragments linked to active 
enzymes such as oxidases and peroxidases that are struc-
turally complex and consequently difficult to express cor-
rectly in bacteria. However, the recent report describing 
the expression in Aspergillus of a nanobody-glucoamylase 
fusion [65] does not provide sufficient information con-
cerning yields and glycosylation patterns to evaluate the 
robustness of the method. Probably, the lack of a ready-
to-use platform for cloning and expression discouraged 
many researchers to test filamentous fungi as a microbial 
cell factory for antibody fragment production. Another 
niche expression system that has been occasionally used 
to express recombinant antibody fragments and recon-
stituted IgG-like molecules is the Leishmania tarento-
lae eukaryotic parasite [66, 67]. The putative advantages 
of this method should reside in its codon usage but the 
reported yields are very low and probably do not justify 
the investment necessary to set this platform in a lab 
already equipped for recombinant production in another 
organism.
Insect cells and larvae have been proposed as nano-
body expression living biofactories [68, 69]. Specifically, 
Trichoplusia ni larvae have been transformed by means 
of the efficient Improved Baculovirus Expression Sys-
tem to produce neutralizing nanobodies directed against 
diarrhea-inducing rotavirus A [69]. The characterization 
of the resulting VHHs indicated that they were functional 
but the shown data are too preliminary to assess the real 
benefit of this production approach in terms of simplic-
ity, cost-efficiency, and antibody quality.
Exploiting plants for antibody production
Recombinant antibody fragments have been successfully 
produced in different higher plants. For instance, an anti-
murine TNF nanobody expressed in and purified from 
rice seeds was effective in neutralizing its antigen and 
suppressing the progression of collagen-induced arthri-
tis in mice [70]. The claimed advantages of this approach 
with respect to microbial protein factories are low pro-
duction costs, scalability, reduced safety issues such as 
toxin and virus contaminations, controlled N-glycosyla-
tion, and the possibility to concentrate the product in 
specific organs, usually seeds or leaves. Nevertheless, the 
final antibody concentration in plant organs is generally 
low (not exceeding hundreds of mg/kg plant, with anti-
bodies representing usually less than 5 % of the total seed 
proteins and less than 1  % of leaf proteins). The down-
stream processing is the major system drawback since the 
diluted target product is mixed with a high load of solu-
ble and particulate contaminants that require demanding 
integrated technological procedures for their removal 
[71]. Furthermore, recombinant protein production can 
induce physiological stress in the host plants resulting in 
the accumulation of heterogeneous products [72]. The 
involved mechanisms are not yet completely understood 
but recently it was demonstrated that the expression of 
VHH-Fc and scFv-Fc fusions trigger unfolded protein 
response in Arabidopsis seeds [73]. The most surprising 
result in this study was that neither the antibody expres-
sion levels nor the intrinsic structural stability of the 
constructs led to significant response differences. This 
observation suggests that the critical threshold for stress 
response is probably low, whereas other factors, such as 
the environmental conditions during seed development 
might contribute to final protein quality and yields. In 
general, the biophysical characterization of the antibodies 
expressed in plants have not been thoroughly addressed 
because the emphasis was rather placed on the (residual?) 
functionality of the purified material. Bivalent reconsti-
tuted Fc-VHH antibodies produced in Arabidopsis and 
Nicotiana benthamiana appeared partially degraded 
after the purification step but resulted effective in neu-
tralizing avian influenza virus [74] and the α-cobratoxin 
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venom [75]. Also in other cases the structural heteroge-
neity of antibodies produced in plants does not appear to 
compromise significantly their functionality [72, 76–78], 
but it can probably complicate their acceptance as thera-
peutics. Likely, the methodology still requires the opti-
mization of the expression conditions and of the binder 
formats. Forcing the antibody fragment accumulation in 
specific sub-cellular compartments and the use of plant 
codons, specific promoters, fusion partners, and tags can 
increase the final yields of stable recombinant antibodies 
[79–82], although the optimal stabilizing combination 
seems to be rather antibody-specific, as exemplified in 
the case of the fusion of VHHs with different Fc domains 
[77].
Immunogenicity can be induced by proteins expressed 
in higher-plant due to the presence of some plant-specific 
sugar residues. The problem has been addressed by using 
RNA interfering technology to down-regulate glycosyla-
tion. A more elegant and definitive alternative was the 
engineering of Nicotiana benthamiana and of the moss 
Physcomitrella patens to obtain fully human N-glyco-
sylation [83, 84]. Furthermore, such moss is suitable for 
photobioreactor production of antibody fragments [85] 
as well as of therapeutic IgG antibodies with superior 
ADCC (antibody-dependent cell-mediated cytotoxicity) 
compared to the same constructs recovered from mam-
malian cultures [86].
Also micro-algae can represent a valid antibody fac-
tory. The unicellular organism Chlamydomonas rein-
hardtii was able to express functional immunotoxins in 
both scFv- and IgG-like formats [87]. These large macro-
molecules have very complex structures that are difficult 
to recover correctly folded in most of the recombinant 
expression systems and this evidence can justify the 
interest in this protein factory.
A meaningful line of research is aimed at developing 
transgenic crops able to produce antifungal recombi-
nant antibodies that neutralize pathogens in  vivo. The 
approach is not absolutely new, but its efficacy strongly 
profited from the late technological progresses. By using 
such a strategy, it was possible to develop crops tolerant 
to different phytopathogen infections such as Brassica 
napus resistant to anti-Sclerotinia sclerotiorum scFvs 
[88], Ciitrus tolerant to Citrus tristeza virus [89], and 
soybean resistant to the Fusarium virguliforme toxin-1 
that induces the sudden death syndrome [90].
Neutralizing recombinant antibody fragment expression 
for direct therapeutic applications
In one of the previous sections we have seen how Lac-
tobacilli overexpressing anti-viral antibody fragments 
can be directly used as an effective “therapeutic food”. 
It is possible because a relatively small volume of their 
culture delivers enough functional antibodies to miti-
gate the disease symptoms [31, 33]. Vegetal organisms 
can be exploited as factories for antibody production and 
for expressing those antibody fragments that can protect 
them from phytopathogens [88–90] but would a plant-
based diet be able to provide therapeutic antibody doses 
sufficient to induce a beneficial effect in fed mammali-
ans? There are promising results indicating the feasibility 
of such a smart development by which plant-producing 
recombinant antibodies might provide “functional food” 
with direct therapeutic effect. Transgenic rice has been 
engineered to accumulate neutralizing anti-rotavirus 
nanobodies in its seeds (MucoRiseARP1) [91]. The idea is 
that of protecting human populations against life-threat-
ening diarrhea by feeding people with antibody-enriched 
seeds because rice is already part of their daily diet. Fol-
lowing the engineering of plants to suppress the upload 
of endogenous storage proteins, the nanobodies accumu-
lated in the seeds at sufficiently high concentrations (g/
kg of total weight and 11.9 % of total protein) to be effec-
tive in vivo as a prophylactic medicament. Furthermore, 
neutralizing nanobodies are water-soluble, resistant 
to both boiling and long-term storage (at least 1  year), 
and do not rely on cold-chain transport and storage. 
These features render the mutant rice not a simple basic 
research proof-of-principle but a product that could be 
potentially adopted by final users. In animal model the 
results seem very promising since even immunodeficient 
mice fed with MucoRiseArp1 resulted significantly pro-
tected against rotavirus infections. The strategy as well 
as the probable legal and cultural resistance is the same 
as described above for anti-virus neutralizing nanobod-
ies expressed in Lactobacillus. It also reminds the logic 
that led to the development of the “Golden-rice” that was 
designed for providing a cheap source of beta-carotene 
to integrate the dietary Vitamin A shortage in rice-eating 
populations [92]. Hopefully they will not share the same 
tormented story. Another meaningful example of thera-
peutic plant is given by the transgenic peas accumulating 
anti-Eimeria neutralizing scFvs in their seeds. Chickens 
fed with them showed significant mitigation against the 
parasite-induced coccidiosis [93].
A different therapeutic approach considers the adeno-
virus vector-dependent expression of a hetero-trimer 
composed of VHHs specific for independent epitopes of 
both Stx1 and Stx2 Shiga toxins. The expression vector 
is delivered by a single intramuscular injection and the 
resulting VHH-based neutralizing agent is released to 
the circulation. As the consequence of effective and sys-
temic toxin targeting, the methodology resulted highly 
protective against hemolytic-uremic syndrome in piglet 
model [94] and, as a vaccination method, could represent 
a valuable curative approach for a pathology for which no 
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suitable remedy is available. Another peculiar exploita-
tion of VHH in vivo expression has been proposed by De 
Vooght et al. [95] for impairing the tsetse fly-dependent 
spreading of trypanosome parasites. The authors demon-
strated that it was possible to stably infect the fly popu-
lation with the genetically engineered bacterial symbiont 
Sodalis glossinidius expressing a strong anti-trypano-
soma nanobody. The nanobodies were efficiently secreted 
by transformed bacteria in  vitro [96] and in  vivo [95] 
and such bacteria were transmitted—although not very 
efficiently—in the progeny and promoted the accumu-
lation of the trypanolytic nanobodies in several tissues 
among which the midgut that is an obligatory environ-
ment for the trypanosome development. The paper does 
not clearly demonstrate that is possible to select long-
term paratransgenic tsetse populations in which the 
parasite transmission is impaired by the nanobody activ-
ity. Nevertheless, it evidences the drawbacks that must 
be removed to achieve this goal, such as the preventive 
elimination of the wild type bacterial population to avoid 
competition with the recombinant bacteria and the selec-
tion of nanobodies structurally resistant to the acidic and 
proteolytic conditions typical of midgut.
Another innovative development concerns the possi-
bility to use plant-expressed antibodies for environmen-
tal remediation and by such a way preventing pollution 
conditions that are critical for human health. Specifically, 
Barbi et  al. [97] developed transgenic tobacco express-
ing anti-microcystin-LR antibody fragments that are 
secreted and anchored to plasma membrane in leaf tis-
sues. The membrane-retained antibodies were able to 
bind the microcystin initially present in hydroponic 
medium and formed stable complexes that could be elim-
inated removing the leaves.
Recombinant antibody fragments as effective intrabodies
VHHs are often stable in the absence of disulfide bonds 
[98–100]. This characteristic makes them valuable tools 
for cell biology studies [101] as well as candidates for 
therapeutic applications based on their expression and 
accumulation as intrabodies directly in the cytoplasm/
nucleus of the host cells. In this subcellular compart-
ment they can neutralize the corresponding antigen and 
block its activity, as already demonstrated in the case of 
anti-viral VHHs [98, 99]. In the specific case of the anti-
Rev VHH Nb190 that is able to suppress HIV-1 replica-
tion, cells stably expressing the intrabody were protected 
against the virus-induced cytopathogenic effect [102].
Different strategies have been developed in order to 
select directly for functional recombinant intrabod-
ies. A C-terminal GFP protein allowed for the fluores-
cence-based light-microscopy screening of the clones 
that expressed folded nanobodies binding selected 
cellular structures [103]. However, the original method 
is demanding because the evaluation is made individu-
ally for each clone. Furthermore, the folding of several 
VHHs depended on DsbC isomerase and stabilizing tags 
that would not be available in clinical settings. Conse-
quently, more convenient approaches have been consid-
ered and recently different variations of the two-hybrid 
technology were successfully applied for isolating both 
scFv and VHH intrabodies [100, 104–106]. Mukhtar 
and colleagues [104] successfully used the yeast two-
hybrid technology to isolate human scFv intrabodies 
against nucleoproteins involved in influenza virus rep-
lication and transcription. Such intrabodies strongly 
bound their antigens and modified their cellular distri-
bution and accumulation rate. When applied to porcine 
circovirus type 2-immunized VHH collections, yeast 
two-hybrid libraries enabled the isolation of intrabod-
ies suitable for ELISA and immunocytochemistry on 
infected cells [105]. More recently, some VHHs target-
ing HIV-1 proteins have been isolated by Sos Recruit-
ment System, a variation of the classical two-hybrid 
methodology in which the bait-prey interaction hap-
pens in the cytoplasm instead of the nucleus [100]. This 
alternative should prevent failures in all of the cases in 
which the folding efficiency of one of the two interact-
ing polypeptides suffers from the conditions present in 
the nucleus milieu. However, only one of the selected 
candidates described in the paper was able to bind its 
viral antigen in the cytoplasm of eukaryotic cells leading 
to its delocalization and despite the strong binding the 
nanobody could not impair the cytostatic and apoptotic 
effects promoted by the antigen [100]. The results con-
firm that the approach still needs to be improved but can 
be suitable for identifying functional binders useful for 
studying the molecular mechanisms regulating pathogen 
proteins. On the other hand, they question the hypoth-
esis of using antibodies for buffering pathogenic factors 
because incomplete neutralization could determine the 
approach failure, whereas antibody excessive accumu-
lation could result toxic for the host cell. The problem 
could also lie in the antibody quality obtained by yeast 
selection methods since the low transfection efficiency 
of this organism limits the overall original clone vari-
ability. Therefore, transposing the two-hybrid principle 
into a bacterial system makes sense due to higher trans-
formation efficiency i.e. a larger clonal diversity would 
become available for selection. The suitability of bacte-
rial two-hybrid for the selection of VHHs was demon-
strated by Pellis et al. [106] who succeeded in recovering 
functional intrabodies directed against GFP, HIV-1 inte-
grase, and T. vivax nucleoside hydrolase. The nanobodies 
had stability and binding characteristics similar to those 
of VHHs isolated by phage display libraries constructed 
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using the same RNA pool and, in some cases, the same 
clone was recovered by both selection methods. The 
authors underline how important was having used mate-
rial from immunized animals since somatic maturation 
would have provided clones of sufficient binding affinity 
for obtaining effective two-hybrid coupling. However, 
most of the selected clones had affinity in the nanomo-
lar range, namely binding constants that can be normally 
recovered panning sufficiently large pre-immune librar-
ies [107]. Consequently, these should be considered 
also for this application. The results recently obtained 
using cytoplasmic Retained Display [108] confirm that 
pre-immune libraries are suitable for direct intrabody 
recovery, in this specific case scFvs with fixed human 
framework and CDR1/CDR2, and which can tolerate 
CDR3 diversification.
Any help from in silico resources?
Antibody fragment final yields are clearly influenced by 
their propensity to misfold and aggregate. A first step 
for the selective screening of stable binders issued from 
phage display libraries can be achieved before starting the 
panning procedure by introducing a heating treatment 
of the phage population [109]. Since thermal stability 
and the capacity to refold into native structure inversely 
correlate with aggregation readiness, the heat-resistant 
clones are on average more stable than precipitated ones 
and can be purified by incubation at high temperatures 
[110]. Bioinformatics and protein modeling could fur-
ther help in identifying critical residues able to improve 
the stability of the recombinant antibodies selected after 
panning. This approach should be considered, although 
it is difficult to identify a consensus about the hot spots 
even in the case of simple single-domain molecules such 
as the VH(H)s [111–113].
Conclusions
Protein complexity implies the necessity of identifying 
customized answers to the variable problems related to 
their production. In the case of antibody fragments, the 
yields of single binders can change dramatically due to 
minimal sequence variations. Consequently, one can-
not expect to obtain a single optimal universal produc-
tion method, but rather should be aware of different 
options suitable for improving the final results. Many of 
the publications reviewed in this work share a common 
aim—the production of application-specific immune-
reagents rather than naked antibodies to use indiscrimi-
nately—and complimentary strategies to accomplish 
it. Therefore, antibodies fragments are often already 
selected in vitro with the aim to recover clones possess-
ing determined features such as epitope-specificity or 
neutralizing activity, then cloned as fusions with appro-
priate effector proteins, and finally diversified expression 
systems are chosen for yielding application-specific func-
tional molecules (Table 1). The overall production design 
largely varies in terms of complexity but it must provide 
reagents suitable for the actual final needs. On the one 
extreme of the scale, simplified systems such as antibody 
displaying cells that can be used without any purifica-
tion step are suitable for some simple immune-detection 
applications and their exploitation makes sense because 
of simplicity and low costs. On the other extreme, very 
sophisticated strategies have been successfully imple-
mented for preventing pathogen aggression in  vivo. In 
between, smart applications such as the development of 
immune-effectors and antibody-based functional food 
that work because the antibody fragments have been 
developed according to criteria that take carefully in 
account the in  vivo physiological conditions in which 
they will operate.
Table 1 Recombinant antibody production: hot topics and examples
Recombinant antibodies are currently used in multiple applications which require the production of large amounts of qualitatively well-defined reagents that need 
as few as possible post-purification steps before being ready for the final application. Major biotechnological needs and representative examples of meaningful 
strategies for their accomplishment are listed below
Antibody applications Opportunity and challenges Achievement reports (references)
Protein delivery Fusions of Ab fragments with active proteins (IL1, toxins, chromophores,…) [4, 5, 12, 16, 87]
BiTE Bispecific T-cell engager [29]
Bispecific activity Possibility to interfere or to join two different pathways [30]
Cell display Purification-independent methods for inexpensive Ab production [31, 33, 47, 48, 97]
Viral nanoparticles Development of self-assembling multivalent structures [56]
In vivo expression and activity Production of pathogen-neutralizing Abs directly in food and animals [88, 90, 91, 93, 95]
Immunomodulation Effective glycosylation for precise targeting and CDC/ADCC [28, 76, 85, 86]
Cargo delivery Ab chemical functionalization for ADC, radiotherapy, and imaging [57]
Bacterial delivery Immune-response and accumulation of active molecules [45, 46]
Intrabodies Necessity to fold into active form in cell reducing cytoplasm [100, 105, 106]
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Altogether, the picture looks optimistic because of 
the many published achievements. Nevertheless, the 
drawback of the present model for research production 
dissemination is its unbalance towards the exclusive pub-
lication of positive results. The consequence is that one 
has access to success stories but knows very little about 
conditions that resulted in failures and that would be use-
ful to know in order to avoid similar mistakes. Systematic 
comparisons based on combinatorial approaches [114] 
and benchmarking initiatives [115, 116] are extremely 
useful to evaluate methods, experimental sets or rea-
gents but are still rare in the field of recombinant anti-
body production [27, 60, 78, 86, 117]. Another observed 
limit is represented by the publication of papers in which 
controls and characterization data necessary to assess 
the reliability of the claimed conclusions are missing. 
For instance, data reporting yield improvement should 
be considered with some caution in the absence of con-
trol results showing that the antibody functionality is 
not affected by the quantitative increase since absolute 
and functional yields might be not coincident. Unluck-
ily, the presentation of a complete set of control data is 
rare and it is a pity because potentially good ideas remain 
unfulfilled when reliable information is diluted in the 
presence of ambiguous results. Accordingly, methods 
presented without preliminary scientific reviewing, such 
as patent applications [118], are not discussed in this 
work. Probably, the community (authors, editors, fund-
ing agencies) should take more seriously the necessity 
to request minimal standards of biophysical [119] and 
functional characterization of immune-reagents and to 
reward the attempts to improve this praxis [120].
Summarizing and apart from “still-to-prove” options, 
the positive news is that new effective methodologies are 
available (Table 2). The actual limit resides in the fact that 
an up-to-date scientific work requires constantly increas-
ing amount of skills (and sometimes new expensive 
equipment) for covering all the project steps optimally. 
The consequence is that in small labs some innovations 
might be slow to be implemented and some steps are 
consequently performed with sub-optimal techniques. 
As an example, the multifactorial statistical Design of 
Experiment methodology [121] would be beneficial in 
most of the works aimed at optimizing the production 
conditions and at characterizing the antibody binding 
features. However, despite the positive reports obtained 
Table 2 Summary of the evaluated expression systems for recombinant antibody production
Expression organism Method robustness: specificities References (for unusual organisms)
Escherichia coli Prokaryotic gold standard, different methodologies –
Lactobacillus paracasei Effective diet therapy [31, 36]
Lactobacillus rhamnosus Effective diet therapy [32]
Lactobacillus plantarum Effective cargo in vivo [46]
Bifidobacterium longum Diet therapy to be demonstrated [35]
Pseudoalteromonas haloplanktis Protein folding at low temperature: high energy needs? [37, 38]
Brevibacillus choshinensis Highly productive for VHHs [39–41]
Bacillus megaterium No shown advantage [42]
Corynebacterium glutamicum No shown advantage [43]
Pseudomonas putida FDA biosafety certificate [44]
Salmonella typhimurium Suitable for display and in vivo cargo applications, biosafe [45]
Pichia pastoris Eukaryotic gold standard –
Saccaromyces cerevisiae Suitable for engineering –
Schizosaccharomyces pombe No shown advantage [58]
CHO Industrial gold standard: no shown advantage at research lab level [63]
HEK293 No shown advantage at research lab level [64]
Trichoderma reesei Not thoroughly characterized [61]
Aspergillus spp. Not thoroughly characterized [61]
Leishmania tarentolae Favorable codon usage, low yields [66, 67]
Trichoplusia ni Positive preliminary results [69]
Arabidopsis thaliana Product heterogeneity [73, 74]
Nicotiana benthamiana Product heterogeneity [75]
Oryza sativa Optimized yields and quality [91]
Physcomitrella patens Suitable for photoreactor, promising for IgGs [84–86]
Chlamydomonas reinhardtii Promising for large immune-reagents [87]
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also with antibodies [122–125], it is not largely used in 
academic labs because it requires a critical initial time 
investment for its setting. The same reasoning can be 
formulated for any specific expertise that participates 
to a project that—for instance—starts with the panning 
design to finish with a clinical application. The necessity 
for collaborations is evident but maybe the profession-
als of the recombinant protein (antibody) production 
should think about what competences would maximally 
qualify their contribution to projects that become more 
and more multidisciplinary and that should avoid bot-
tlenecks at any step of their development. Finally, it can 
be difficult to switch from E. coli to—let say—the moss 
Physcomitrella patens or the microalgae Chlamydomonas 
reinhardtii for producing high-quality immune-reagents 
but why not to consider this strategy if, in the long term, 
it can result more convenient than idle time investment 
in a more familiar platform with clear intrinsic limits?
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